A headline about a medicine and “brain health” can bring a lot of hope, especially if Alzheimer’s disease has touched your family. It can also leave out the difference between a lab observation, a pattern in medical records and a trial that actually assigned people to treatment.
Two large human trials looked at oral semaglutide in people with early symptomatic Alzheimer’s disease. The trials did not show that oral semaglutide slowed cognitive and functional decline on their main measure compared with placebo at two years. That result answers an important question, with boundaries worth understanding.
Why were researchers interested?
Some earlier studies observed patterns linking GLP-1 medicines with brain-related outcomes. Laboratory work also gave scientists reasons to ask whether these medicines might affect processes relevant to the brain.
An observation can help generate a question. It cannot by itself establish that a medicine caused the observed difference. People taking different treatments may differ in their health, access to care and many other ways that are difficult to account for completely.
That’s why randomized trials are valuable. Researchers assign participants to treatment groups by chance and compare outcomes under a planned protocol.
Who took part in evoke and evoke+?
The two trials enrolled 3,808 adults in total. Participants were 55 to 85 years old and had early symptomatic Alzheimer’s disease confirmed with a relevant biological marker. Some had mild cognitive impairment and others had mild dementia due to Alzheimer’s.
Participants were assigned to oral semaglutide or placebo. Researchers measured change in a standard assessment of cognition and function at 104 weeks. The question was whether treatment slowed progression in people who already had symptoms.
That is different from asking whether a medicine prevents Alzheimer’s from developing in people who have no symptoms. A progression trial does not automatically answer a prevention question, even when the two topics appear in the same headline.
What did the trials find?
On the primary measure, the semaglutide groups did not show a statistically significant slowing of cognitive and functional decline compared with placebo at week 104. Adverse events were also recorded and occurred more often in the semaglutide group.
This is not a footnote to a positive story. It is the main result of the question the trials were designed to test. At the same time, it should not be stretched into a claim about every possible GLP-1 medicine, every neurological condition or every future research question.
What about memory or “brain fog”?
People use those words to describe many different experiences. Changes in sleep, stress, nutrition, medicines and health conditions can all be relevant to a conversation about memory or concentration.
If a new or worsening problem concerns you, tell your clinician what you’ve noticed and when it started. A loved one may be able to share observations too, if you want their help. Your care team can consider your history and decide what assessment makes sense.
Don’t start a medicine for dementia prevention, or stop an existing prescription, based on a social post. If you take semaglutide for another reason and have questions, discuss its benefits and risks for that reason with your prescriber.
A few questions for the next headline
Was the study in cells, animals or people? If it was in people, were they randomly assigned a treatment? Did it study prevention, symptom progression or a laboratory marker? What was the main outcome, and did the result support the claim?
Our guide to comparing GLP-1 trial results explains these distinctions. They can make the difference between an intriguing early clue and evidence that answers the question you actually have.